FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
The approval was granted based on data from the Phase III C-POST study.
Therapy Area
Affinia raises $40m for gene therapy development
Oragenics partners Receptor.AI for brain health candidate portfolio
FDA lifts clinical hold on Neurizon’s ALS drug
Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy
McMaster University and MIT discover new antibiotic for IBD
FDA approves mifepristone generic as political abortion war rages on
Amgen’s Phase III data supports FDA label expansion of Repatha
